Relapsing optic neuritis: a multicentre study of 62 patients

Abstract

Background:

Optic neuritis (ON) may be the first symptom of a central nervous system demyelinating, systemic or infectious disease but few patients experience recurrent episodes and have a negative workup.

Objective:

This disorder, named relapsing optic neuritis (RON), is poorly described in the literature and still presents a particular challenge in diagnosis and management.

Methods:

We describe the clinical, laboratory, magnetic resonance imaging (MRI) and disability course of RON in a French cohort of 62 patients, based on a multicentre, retrospective, observational study.

Results:

In our cohort, we identified two distinct groups of RON patients. The first is characterised by relapsing inflammatory optic neuritis (RION, 68%), which is non-progressive, whereas the second presented as a chronic relapsing inflammatory optic neuritis (CRION, 32%), which is progressive. We have noted more cases with steroid dependence in the CRION group than the RION group (42% vs 10%). The long-term visual prognosis was more severe in CRION patients and neuromyelitis optica-immunoglobulin G (NMO-IgG)-positive patients.

Conclusion:

RON is likely a separate entity corresponding to an autoimmune disease that differs from multiple sclerosis (MS), NMO and vasculitis. We provide a new classification system based on a better understanding of RON which could allow an improved management by early treatment of poor prognosis forms.

Keywords

Optic neuritis CRION RON NMO-IgG multiple sclerosis

Get full access to this article

View all access options for this article.

References

Beck

Cleary

Anderson

Jr . A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581–588.

Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727–732.

Ratchford

Quigg

Conger

. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73: 302–308.

Lucchinetti

Kiers

O‘Duffy

. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49: 1413–1418.

Kidd

Burton

Plant

. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003; 126: 276–284.

Matiello

Lennon

Jacob

. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197–2200.

Petzold

Pittock

Lennon

. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2011; 81: 109–111.

Pirko

Blauwet

Lesnick

. The natural history of recurrent optic neuritis. Arch Neurol 2004; 61: 1401–1405.

Lennon

Wingerchuk

Kryzer

. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106–2112.

10.

Wingerchuk

Lennon

Lucchinetti

. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815.

11.

Jarius

Wildemann

AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383–392.

12.

de Seze

Arndt

Jeanjean

. Relapsing inflammatory optic neuritis: Is it neuromyelitis optica? Neurology 2008; 70: 2075–2076.

13.

Jarius

Frederikson

Waters

. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158–162.

14.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2010; 69: 292–302.

15.

Wingerchuk

Lennon

Pittock

. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.

16.

Hochberg

MC.

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

17.

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736–755.

18.

Vitali

Bombardieri

Jonsson

. Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

19.

Pau

Al Zubidi

Yalamanchili

. Optic neuritis. Eye (Lond) 2011; 25: 833–842.

20.

Plant

GT.

Optic neuritis and multiple sclerosis. Curr Opin Neurol 2008; 21: 16–21.

21.

Mata

Lolli

Neuromyelitis optica: An update. J Neurol Sci 2011; 303: 13–21.

22.

de Seze

Lebrun

Stojkovic

. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003; 9: 521–525.

23.

Merle

Olindo

Bonnan

. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114: 810–815.

24.

Monteiro

Fernandes

Apóstolos-Pereira

. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53: 3959–3966.